Gland Pharma Shares in Focus; Announces Strategic CDMO Partnership with a Global Pharma Company

Gland Pharma Limited has entered a strategic manufacturing arrangement with a global pharmaceutical company for a portfolio of sterile injectable products intended for international markets, as per the exchange filings. 

The agreement was announced on August 9, 2026, with the partner's identity kept confidential. 

55 Products Across Three Sites 

The Manufacturing and Supply Agreement covers 55 SKUs, which will be manufactured across three sites. The portfolio includes oncology and non-oncology products in vials, lyophilised vials, ampoules and pre-filled syringes. 

Both complex and conventional injectable formulations are included in the portfolio. 

Full-Service CDMO Arrangement 

Gland Pharma will handle the engagement through a full-service CDMO model covering technology transfer, process development, scale-up, validation, commercial manufacturing and long-term supply. 

Technology transfer activities are planned for completion within two years, while the agreement provides for revenue generation from calendar year 2029. 

$90-100 Million Revenue Potential 

Once the products covered under the agreement are commercialised, the annualised revenue potential has been stated at approximately $90-100 million. 

The agreement also leaves scope for additional products to be added to the existing portfolio. 

Management Commentary 

Gland Pharma Executive Chairman Srinivas Sadu said, “The partnership highlights the confidence global pharmaceutical companies place in Gland Pharma's development, technology transfer, manufacturing, and supply capabilities.” 

He added that the agreement provides long-term revenue visibility and supports the expansion of the company's CDMO business. 

Read More: Kaynes Technology India Share Price in Focus After Q1 FY27 Earnings Results: Total Income Up 37.1% YoY! 

Gland Pharma Share Price Performance   

As of 10 August 2026, at 11:39 AM, Gland Pharma Limited share price was trading at ₹2,642 per share, reflecting a surge of 1.58% from the previous trading session. 

Conclusion 

The new international CDMO arrangement expands Gland Pharma's manufacturing mandate to 55 sterile injectable SKUs across three facilities, with the agreement carrying stated annualised revenue potential of $90-100 million upon commercialisation. 

Want to read stock market updates in Hindi? Angel One News gives comprehensive share market news in Hindi.  

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.  

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.